An editorial on phase 2 results from treating people with obesity or overweight but not diabetes with retatrutide, a triple hormone–receptor agonist, calls the weight loss achieved "unprecedented."
Weight loss is recommended for patients with knee osteoarthritis (KOA), and GLP-1 RAs are approved for weight loss. Early research suggests these drugs might have a disease-modifying effect for KOA.
Researchers propose the use of ratios of vitamin D metabolites that take into account individual differences in vitamin D binding proteins to improve prediction of secondary hyperparathyroidism risk.
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how enthesitis develops.